• citations in SCIndeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:3
  • full-text downloads in 30 days:0


article: 4 from 5  
Back back to result list
2008, vol. 136, iss. 5-6, pp. 295-298
Adrenal incidentaloma in neurofibromatosis type 1
aClinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade
bUniversity of Belgrade, Faculty of Medicine, Institute of Pathology

INTRODUCTION Neurofibromatosis type 1 is one of the most common genetically transmitted diseases with a high index of spontaneous mutations and extremely varied and unpredictable clinical manifestations. It is diagnosed by the existence of certain clinical criteria. The presence of numerous localized cutaneous neurofibromas or a plexiform neurofibroma is virtually pathognomonic of neurofibromatosis type 1. The incidence of pheochromocytoma in neurofibromatosis type 1 is 0.1-5.7%. CASE OUTLINE A 56-year old female patient was admitted for further evaluation of incidental adrenal tumour previously diagnosed on computerized tomography (CT). She had previously unrecognized neurofibromatosis type 1 and a clinical picture which could remind of pheochromocytoma. None of the catecholamine samples in 24 hr urine indicated functionally active pheochromocytoma. Chromogranin A was moderately increased. Decision for operation was made after performing the image techniques. Adrenal incidentaloma had features of pheochromocytoma on abdominal magnetic resonance imaging (MRI), with positive 131I-MIBG (iodine 131-labelled metaiodobenzylguanidine scintigraphy). After being treated with phenoxybenzamine and propranolol, she was operated on. The pathohistological finding showed the case of left adrenal pheochromocytoma. CONCLUSION Detailed diagnostic procedure for pheochromocytoma should be performed with patients having neurofibromatosis type 1 and adrenal incidentaloma. Pheochromocytomas are rare tumours with fatal outcome if not duly recognized and cured.
Jabbour, A.S., Davidović, B.B., Wolf, R. (2006) Rare syndromes. Clinics in dermatology, 24, str. 299-316
Lenders, J.W.M., Eisenhofer, G., Mannelli, M., Pacak, K. (2005) Phaeochromocytoma. Lancet, 366(9486): 665-75
Marx, J.S., Simonds, F.W. (2005) Hereditary hormone excess: Genes, molecular pathways, and syndromes. Endocrine Reviews, 26(5): 615
Murovic, J.A., Kim, H.D., Kline, G.D. (2006) Neurofibromatosis-associated nerve sheath tumors. Neurosurgical FOCUS, 20(1): 1
Opocher, G., Conton, P., Schiavi, F., Macino, B., Mantero, F. (2005) Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer, 4(1): 13-6
Plouin, P.F., Gimenez-Roqueplo, A.P. (2006) Pheochromocytomas and secreting paragangliomas. Orphanet Journal of Rare Diseases, 1(1): 49
Slijepčević, D.Đ., Vujović, S., Nestorović, Z. (2002) Humana klinička endokrinologija. Beograd: Obeležja
Taupenot, L., Harper, K.L., O'Connor, D.T. (2003) The chromogranin-secretogranin family. N Engl J Med, 348(12): 1134-49
Theos, A., Korf, B. (2006) Pathophysiology of neurofibromatosis type 1. Ann Intern Med, 144, str. 842-6
van der Harst, E., de Herder, W.W., Bruining, H.A., i dr. (2000) (123 I) MIBG and (111 In) octreotode uptake in benign and malignant pheochromocytoma. JCEM, 86, str. 685-93


article language: Serbian
document type: Case Report
DOI: 10.2298/SARH0806295T
published in SCIndeks: 23/09/2008

Related records

Medicinski časopis (2015)
Opioid-induced androgen deficiency in males (OPIAD syndrome)
Miljković Milijana, et al.

Srps arh celokup lekarstvo (2013)
Relationships between obesity, lipids and fasting glucose in the menopause
Simoncig-Netjasov Aleksandra, et al.

Med gl Spec bol štit Zlatibor (2010)
Danger called paraganglioma
Marina Đorđe, et al.

show all [8]